Prospects for the manufacture of red cells for transfusion

Jo Mountford, Emmanuel N. Olivier, Marc Turner

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Whilst red cell transfusion is a well established cellular therapy, the problems of insufficiency of supply, transfusion transmitted infections and the requirement for immunological matching persist. The possibility of generating large numbers of O Rh D negative red cells at Good Manufacturing Practice grade as a route to circumvent these issues is therefore an attractive proposition. Significant numbers of erythrocytes can be generated from somatic haematopoietic stem cells, but it seems unlikely that these can provide sufficient volumes for large scale manufacture. However, human embryonic stem cells (hESC) and, potentially, induced pluripotent stem cells (iPSC), may provide a route to this objective. Red cell transfusion is an attractive goal for pluripotent stem cell-derived therapeutics because it is a well-characterised single cell suspension that lacks nucleated cells and has a low expression of human leucocyte antigen molecules, but many challenges remain in translating this cellular therapy to the clinic.

Original languageEnglish (US)
Pages (from-to)22-34
Number of pages13
JournalBritish Journal of Haematology
Volume149
Issue number1
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Induced Pluripotent Stem Cells
Pluripotent Stem Cells
Erythrocyte Count
Adult Stem Cells
HLA Antigens
Hematopoietic Stem Cells
Suspensions
Therapeutics
Infection
Human Embryonic Stem Cells

Keywords

  • Cellular therapy
  • Red cell transfusion
  • Stem cells

ASJC Scopus subject areas

  • Hematology

Cite this

Prospects for the manufacture of red cells for transfusion. / Mountford, Jo; Olivier, Emmanuel N.; Turner, Marc.

In: British Journal of Haematology, Vol. 149, No. 1, 04.2010, p. 22-34.

Research output: Contribution to journalReview article

Mountford, Jo ; Olivier, Emmanuel N. ; Turner, Marc. / Prospects for the manufacture of red cells for transfusion. In: British Journal of Haematology. 2010 ; Vol. 149, No. 1. pp. 22-34.
@article{fb587ad6d602464c895b31da82b4aa12,
title = "Prospects for the manufacture of red cells for transfusion",
abstract = "Whilst red cell transfusion is a well established cellular therapy, the problems of insufficiency of supply, transfusion transmitted infections and the requirement for immunological matching persist. The possibility of generating large numbers of O Rh D negative red cells at Good Manufacturing Practice grade as a route to circumvent these issues is therefore an attractive proposition. Significant numbers of erythrocytes can be generated from somatic haematopoietic stem cells, but it seems unlikely that these can provide sufficient volumes for large scale manufacture. However, human embryonic stem cells (hESC) and, potentially, induced pluripotent stem cells (iPSC), may provide a route to this objective. Red cell transfusion is an attractive goal for pluripotent stem cell-derived therapeutics because it is a well-characterised single cell suspension that lacks nucleated cells and has a low expression of human leucocyte antigen molecules, but many challenges remain in translating this cellular therapy to the clinic.",
keywords = "Cellular therapy, Red cell transfusion, Stem cells",
author = "Jo Mountford and Olivier, {Emmanuel N.} and Marc Turner",
year = "2010",
month = "4",
doi = "10.1111/j.1365-2141.2010.08079.x",
language = "English (US)",
volume = "149",
pages = "22--34",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Prospects for the manufacture of red cells for transfusion

AU - Mountford, Jo

AU - Olivier, Emmanuel N.

AU - Turner, Marc

PY - 2010/4

Y1 - 2010/4

N2 - Whilst red cell transfusion is a well established cellular therapy, the problems of insufficiency of supply, transfusion transmitted infections and the requirement for immunological matching persist. The possibility of generating large numbers of O Rh D negative red cells at Good Manufacturing Practice grade as a route to circumvent these issues is therefore an attractive proposition. Significant numbers of erythrocytes can be generated from somatic haematopoietic stem cells, but it seems unlikely that these can provide sufficient volumes for large scale manufacture. However, human embryonic stem cells (hESC) and, potentially, induced pluripotent stem cells (iPSC), may provide a route to this objective. Red cell transfusion is an attractive goal for pluripotent stem cell-derived therapeutics because it is a well-characterised single cell suspension that lacks nucleated cells and has a low expression of human leucocyte antigen molecules, but many challenges remain in translating this cellular therapy to the clinic.

AB - Whilst red cell transfusion is a well established cellular therapy, the problems of insufficiency of supply, transfusion transmitted infections and the requirement for immunological matching persist. The possibility of generating large numbers of O Rh D negative red cells at Good Manufacturing Practice grade as a route to circumvent these issues is therefore an attractive proposition. Significant numbers of erythrocytes can be generated from somatic haematopoietic stem cells, but it seems unlikely that these can provide sufficient volumes for large scale manufacture. However, human embryonic stem cells (hESC) and, potentially, induced pluripotent stem cells (iPSC), may provide a route to this objective. Red cell transfusion is an attractive goal for pluripotent stem cell-derived therapeutics because it is a well-characterised single cell suspension that lacks nucleated cells and has a low expression of human leucocyte antigen molecules, but many challenges remain in translating this cellular therapy to the clinic.

KW - Cellular therapy

KW - Red cell transfusion

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=77949362084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949362084&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2010.08079.x

DO - 10.1111/j.1365-2141.2010.08079.x

M3 - Review article

C2 - 20151974

AN - SCOPUS:77949362084

VL - 149

SP - 22

EP - 34

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -